Výsledky vyhledávání - "Glenwood D Goss"

Akademický článek

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial

Autor: Jean-Charles Soria, Enriqueta Felip, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Wei Li, Dolores Isla, Salih Z Guclu, Alessandro Morabito, Young J Min, Andrea Ardizzoni, Shirish M Gadgeel, Bushi Wang, Vikram K Chand, Glenwood D Goss

Publikováno v: Современная онкология, Vol 17, Iss 3, Pp 42-52 (2015)

Background. There is a major unmet need for effective treatments in patients with squamous cell carcinoma of the lung. LUX-Lung 8 compared afatinib (an irreversible ErbB family blocker) with erlotinib (a reversible EGFR tyrosine kinase inhibitor), as

Externí odkaz: https://doaj.org/article/d2707293f29543479eb0d50d65f683aa

Zobrazit plný text záznamu

Akademický článek

Focal Adhesion Kinase Inhibitors in Combination with Erlotinib Demonstrate Enhanced Anti-Tumor Activity in Non-Small Cell Lung Cancer.

Autor: Grant A Howe, Bin Xiao, Huijun Zhao, Khalid N Al-Zahrani, Mohamed S Hasim, James Villeneuve, Harmanjatinder S Sekhon, Glenwood D Goss, Luc A Sabourin, Jim Dimitroulakos, Christina L Addison

Publikováno v: PLoS ONE, Vol 11, Iss 3, p e0150567 (2016)

Blockade of epidermal growth factor receptor (EGFR) activity has been a primary therapeutic target for non-small cell lung cancers (NSCLC). As patients with wild-type EGFR have demonstrated only modest benefit from EGFR tyrosine kinase inhibitors (TK

Externí odkaz: https://doaj.org/article/21805c1dece148209f371f94cca74a0d

Zobrazit plný text záznamu

Akademický článek

Histologic and Genotypic Characterization of Lung Cancer in the Inuit Population of the Eastern Canadian Arctic

Autor: Glenwood D. Goss, Johanna N. Spaans, David Huntsman, Timothy Asmis, Natalie M. Andrews Wright, Marc Duciaume, Pardeep Kaurah, Ruth R. Miller, Shantanu Banerji, Harmanjatinder S. Sekhon, Marcio M. Gomes

Publikováno v: Current Oncology, Vol 29, Iss 5, Pp 3171-3186 (2022)

Inuit are the Indigenous Arctic peoples and residents of the Canadian territory of Nunavut who have the highest global rate of lung cancer. Given lung cancer’s mortality, histological and genomic characterization was undertaken to better understand

Externí odkaz: https://doaj.org/article/19fa4df936c2416ab987aef3528518a4

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first‐line platinum chemotherapy in high grade serous ovarian cancer

Publikováno v: Cancer Medicine, Vol 10, Iss 9, Pp 3045-3058 (2021)

Abstract Background In high grade serous ovarian cancer (HGSOC), there is a spectrum of sensitivity to first line platinum‐based chemotherapy. This study molecularly characterizes HGSOC patients from two distinct groups of chemotherapy responders (

Externí odkaz: https://doaj.org/article/8826b110dfd043bcab07785ab9fa87ae

Zobrazit plný text záznamu

Akademický článek

Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung: Final analysis of the randomised phase 3 LUX-Lung 8 trial

Autor: Glenwood D. Goss, Manuel Cobo, Shun Lu, Konstantinos Syrigos, Ki Hyeong Lee, Erdem Göker, Vassilis Georgoulias, Dolores Isla, Alessandro Morabito, Young J. Min, Andrea Ardizzoni, Shaun Bender, Agnieszka Cseh, Enriqueta Felip

Publikováno v: EClinicalMedicine, Vol 37, Iss , Pp 100940- (2021)

Background: LUX-Lung 8 was a randomised, controlled, phase 3 study comparing afatinib and erlotinib as second-line treatment of patients with advanced squamous cell carcinoma (SCC) of the lung. We report the final overall survival (OS) and safety ana

Externí odkaz: https://doaj.org/article/d8fe0d7fea454b01b8c9f6bcd8ec32f9

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání